Boundless Bio Inc. (BOLD) AI Stock Analysis

• Market Cap: $23.50M
• Dividend Yield: N/A
• Average Volume (3M): 178.65K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.88
• Revenue Growth: N/A
• EPS Growth: -0.50%
• Country: US
• Employees: 64
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.62
• Shares Outstanding: 22,385,610
• 10 Day Avg. Volume: 162,533
• 30 Day Avg. Volume: 178,649
• PEG Ratio: -0.01
• Price to Book (P/B): 0.33
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.78
• Enterprise Value/Market Cap: 2.52
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -94.38
• Enterprise Value/Ebitda: -0.93
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -2.59
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: $1.00 ▼(-21.26% Downside)

The score is held down primarily by weak financial performance driven by a pre-revenue model, large ongoing losses, and continued cash burn that implies ongoing funding needs. Technical indicators are roughly neutral and provide only modest support, while valuation is constrained by negative earnings and no stated dividend yield.

Positive Factors

Innovative Pipeline

Boundless Bio's focus on ecDNA biology for cancer therapeutics positions it at the forefront of innovative oncology treatments, potentially leading to breakthrough therapies and a strong competitive edge in the biotechnology sector.

Cash Position

A robust cash position provides Boundless Bio with the financial flexibility to continue its R&D activities and sustain operations without immediate external funding, supporting long-term strategic initiatives.

Clinical Trial Progress

Progress in clinical trials, such as the POTENTIATE trial, indicates advancement in drug development, which is crucial for future commercialization and potential revenue streams, enhancing the company's growth prospects.

Negative Factors

Pre-Revenue Model

Operating as a pre-revenue company, Boundless Bio faces significant financial risk as it relies on external funding and successful product development to achieve profitability, which may impact long-term sustainability.

Ongoing Losses

Persistent losses highlight the challenge of covering operating expenses without revenue, which could strain resources and necessitate further funding rounds, potentially diluting shareholder value.

Cash Burn

High cash burn rates indicate that the company is consuming cash rapidly, which may limit its ability to invest in growth opportunities and necessitate additional capital raises, affecting long-term financial health.

Boundless Bio Inc. Business Overview & Revenue Model

Company Description

Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California.

How the Company Makes Money

Boundless Bio Inc. generates revenue primarily through the development and commercialization of its proprietary therapies targeting ecDNA in cancer cells. The company may receive funding through partnerships, collaborations, and licensing agreements with other pharmaceutical companies, which provide financial support for its research and development activities. Additionally, revenue could be derived from milestone payments and royalties related to the successful advancement and commercialization of its therapeutic products. Public and private funding rounds may also contribute to its financial resources, enabling ongoing research and clinical trials.

Boundless Bio Inc. Financial Statement Overview

Summary

Overall financial profile is weak: the company is pre-revenue with large ongoing losses (TTM net loss ~$61.8M) and persistent cash burn (TTM FCF ~$-52.7M). The main offset is an improved balance sheet versus prior years with positive equity (TTM ~$110.2M) and moderate leverage (TTM debt-to-equity ~0.40), but continued funding dependence remains a key risk.

Income Statement

The income statement profile is very weak: the company generates no revenue across annual periods and in TTM (Trailing-Twelve-Months), while losses remain large (TTM net loss of about $61.8M). Profitability is structurally negative with deeply negative operating results (TTM EBIT around -$67.8M), though losses improved modestly versus 2024 (net loss about $65.4M), suggesting some cost discipline. The key weakness is the lack of commercial revenue to absorb operating expenses, keeping margins heavily negative and making near-term earnings visibility limited.

Balance Sheet

The balance sheet is mixed but improved versus earlier years. Stockholders’ equity is positive in 2024 ($150.6M) and TTM ($110.2M) after being negative in 2021–2023, indicating recapitalization and a stronger capital base. Leverage appears moderate on the latest figures (TTM debt-to-equity ~0.40; total debt ~$49.8M), but equity has stepped down from 2024 to TTM, and returns on equity remain negative in 2024 and TTM due to ongoing losses—highlighting continued reliance on financing to fund operations.

Cash Flow

Cash flow generation is weak with persistent cash burn: TTM operating cash flow is about -$52.1M and TTM free cash flow is about -$52.7M. While cash burn improved versus 2024 (operating cash flow about -$60.8M; free cash flow about -$63.4M), the trend is still negative and TTM free cash flow declined versus 2024 per the provided growth figure. A relative positive is that free cash flow roughly tracks reported losses (TTM free cash flow to net income ~1.02), implying losses are largely reflected in cash outflows rather than being masked by accounting items.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2018
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-627.00K	-1.09M	0.00	0.00	0.00	0.00
EBITDA	-63.93M	-64.28M	-53.84M	-45.53M	-24.62M	-121.36M
Net Income	-61.76M	-65.36M	-49.43M	-45.90M	-25.21M	-128.82M
Balance Sheet
Total Assets	168.72M	206.41M	129.89M	76.83M	113.72M	472.56M
Cash, Cash Equivalents and Short-Term Investments	117.57M	152.11M	120.75M	66.72M	73.03M	414.31M
Total Debt	49.76M	47.63M	2.19M	5.18M	377.00K	7.07M
Total Liabilities	58.55M	55.77M	256.98M	158.53M	151.91M	29.80M
Stockholders Equity	110.17M	150.64M	-127.08M	-81.70M	-38.19M	442.75M
Cash Flow
Free Cash Flow	-52.70M	-63.38M	-47.49M	-40.66M	-25.28M	-119.59M
Operating Cash Flow	-52.12M	-60.84M	-46.85M	-39.60M	-23.25M	-107.98M
Investing Cash Flow	26.65M	-26.10M	-38.26M	16.13M	-59.28M	-185.05M
Financing Cash Flow	230.00K	89.82M	97.90M	126.00K	105.53M	398.46M

Boundless Bio Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.27
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BOLD, the sentiment is Negative. The current price of 1.27 is above the 20-day moving average (MA) of 1.22, above the 50-day MA of 1.19, and above the 200-day MA of 1.24, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 26.68 is Positive, neither overbought nor oversold. The STOCH value of 24.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BOLD.

Boundless Bio Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ALXO	61 Neutral	$108.98M	-0.99	-118.95%	―	―	31.98%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CLGN	48 Neutral	$20.47M	-1.58	-92.74%	―	280.77%	32.82%
BOLD	45 Neutral	$23.50M	-0.38	-44.88%	―	―	-0.50%
BRNS	44 Neutral	$28.58M	-0.37	-62.30%	―	-100.00%	-26.30%
ALGS	42 Neutral	$43.51M	-0.36	-141.82%	―	-55.88%	6.14%
PLUR	40 Underperform	$30.54M	-1.07	―	―	121.74%	24.75%